Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
1197 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Alzheimer's Disease - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H1 2015', provides an overview of the Alzheimer's Disease's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 11 Alzheimer's Disease Overview 12 Therapeutics Development 13 Alzheimer's Disease - Therapeutics under Development by Companies 15 Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 33 Alzheimer's Disease - Pipeline Products Glance 41 Alzheimer's Disease - Products under Development by Companies 45 Alzheimer's Disease - Products under Investigation by Universities/Institutes 73 Alzheimer's Disease - Companies Involved in Therapeutics Development 83 Alzheimer's Disease - Therapeutics Assessment 285 Drug Profiles 306 Alzheimer's Disease - Recent Pipeline Updates 968 Alzheimer's Disease - Dormant Projects 1089 Alzheimer's Disease - Discontinued Products 1122 Alzheimer's Disease - Product Development Milestones 1132 Appendix 1138
List of Tables Number of Products under Development for Alzheimer's Disease, H1 2015 71 Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H1 2015 72 Number of Products under Development by Companies, H1 2015 74 Number of Products under Development by Companies, H1 2015 (Contd..1) 75 Number of Products under Development by Companies, H1 2015 (Contd..2) 76 Number of Products under Development by Companies, H1 2015 (Contd..3) 77 Number of Products under Development by Companies, H1 2015 (Contd..4) 78 Number of Products under Development by Companies, H1 2015 (Contd..5) 79 Number of Products under Development by Companies, H1 2015 (Contd..6) 80 Number of Products under Development by Companies, H1 2015 (Contd..7) 81 Number of Products under Development by Companies, H1 2015 (Contd..8) 82 Number of Products under Development by Companies, H1 2015 (Contd..9) 83 Number of Products under Development by Companies, H1 2015 (Contd..10) 84 Number of Products under Development by Companies, H1 2015 (Contd..11) 85 Number of Products under Development by Companies, H1 2015 (Contd..12) 86 Number of Products under Development by Companies, H1 2015 (Contd..13) 87 Number of Products under Development by Companies, H1 2015 (Contd..14) 88 Number of Products under Development by Companies, H1 2015 (Contd..15) 89 Number of Products under Development by Companies, H1 2015 (Contd..16) 90 Number of Products under Investigation by Universities/Institutes, H1 2015 92 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 93 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 94 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 95 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 96 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 97 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 98 Comparative Analysis by Late Stage Development, H1 2015 99 Comparative Analysis by Clinical Stage Development, H1 2015 100 Comparative Analysis by Early Stage Development, H1 2015 101 Comparative Analysis by Unknown Stage Development, H1 2015 102 Products under Development by Companies, H1 2015 103 Products under Development by Companies, H1 2015 (Contd..1) 104 Products under Development by Companies, H1 2015 (Contd..2) 105 Products under Development by Companies, H1 2015 (Contd..3) 106 Products under Development by Companies, H1 2015 (Contd..4) 107 Products under Development by Companies, H1 2015 (Contd..5) 108 Products under Development by Companies, H1 2015 (Contd..6) 109 Products under Development by Companies, H1 2015 (Contd..7) 110 Products under Development by Companies, H1 2015 (Contd..8) 111 Products under Development by Companies, H1 2015 (Contd..9) 112 Products under Development by Companies, H1 2015 (Contd..10) 113 Products under Development by Companies, H1 2015 (Contd..11) 114 Products under Development by Companies, H1 2015 (Contd..12) 115 Products under Development by Companies, H1 2015 (Contd..13) 116 Products under Development by Companies, H1 2015 (Contd..14) 117 Products under Development by Companies, H1 2015 (Contd..15) 118 Products under Development by Companies, H1 2015 (Contd..16) 119 Products under Development by Companies, H1 2015 (Contd..17) 120 Products under Development by Companies, H1 2015 (Contd..18) 121 Products under Development by Companies, H1 2015 (Contd..19) 122 Products under Development by Companies, H1 2015 (Contd..20) 123 Products under Development by Companies, H1 2015 (Contd..21) 124 Products under Development by Companies, H1 2015 (Contd..22) 125 Products under Development by Companies, H1 2015 (Contd..23) 126 Products under Development by Companies, H1 2015 (Contd..24) 127 Products under Development by Companies, H1 2015 (Contd..25) 128 Products under Development by Companies, H1 2015 (Contd..26) 129 Products under Development by Companies, H1 2015 (Contd..27) 130 Products under Investigation by Universities/Institutes, H1 2015 131 Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 132 Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 133 Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 134 Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 135 Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 136 Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 137 Products under Investigation by Universities/Institutes, H1 2015 (Contd..7) 138 Products under Investigation by Universities/Institutes, H1 2015 (Contd..8) 139 Products under Investigation by Universities/Institutes, H1 2015 (Contd..9) 140 Alzheimer's Disease - Pipeline by AB Science, H1 2015 141 Alzheimer's Disease - Pipeline by AbbVie Inc., H1 2015 142 Alzheimer's Disease - Pipeline by AC Immune SA, H1 2015 143 Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc., H1 2015 144 Alzheimer's Disease - Pipeline by Acelot, Inc., H1 2015 145 Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals, Inc., H1 2015 146 Alzheimer's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 147 Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H1 2015 148 Alzheimer's Disease - Pipeline by AFFiRiS AG, H1 2015 149 Alzheimer's Disease - Pipeline by Alector LLC, H1 2015 150 Alzheimer's Disease - Pipeline by ALSP, Inc., H1 2015 151 Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H1 2015 152 Alzheimer's Disease - Pipeline by Alzinova AB, H1 2015 153 Alzheimer's Disease - Pipeline by AlzProtect SAS, H1 2015 154 Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 155 Alzheimer's Disease - Pipeline by Amgen Inc., H1 2015 156 Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp., H1 2015 157 Alzheimer's Disease - Pipeline by Angita B.V., H1 2015 158 Alzheimer's Disease - Pipeline by Apodemus AB, H1 2015 159 Alzheimer's Disease - Pipeline by Araclon Biotech, S.L., H1 2015 160 Alzheimer's Disease - Pipeline by Archer Pharmaceuticals, Inc., H1 2015 161 Alzheimer's Disease - Pipeline by ArmaGen Technologies, Inc., H1 2015 162 Alzheimer's Disease - Pipeline by Artery Therapeutics, Inc., H1 2015 163 Alzheimer's Disease - Pipeline by Astellas Pharma Inc., H1 2015 164 Alzheimer's Disease - Pipeline by AstraZeneca PLC, H1 2015 165 Alzheimer's Disease - Pipeline by Ausio Pharmaceuticals, LLC, H1 2015 166 Alzheimer's Disease - Pipeline by Avergen Ltd, H1 2015 167 Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2015 168 Alzheimer's Disease - Pipeline by Axerion Therapeutics, Inc., H1 2015 169 Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H1 2015 170 Alzheimer's Disease - Pipeline by Axxam SpA, H1 2015 171 Alzheimer's Disease - Pipeline by Azevan Pharmaceuticals, Inc., H1 2015 172 Alzheimer's Disease - Pipeline by BioArctic Neuroscience AB, H1 2015 173 Alzheimer's Disease - Pipeline by biOasis Technologies Inc., H1 2015 174 Alzheimer's Disease - Pipeline by Biogen Idec Inc., H1 2015 175 Alzheimer's Disease - Pipeline by Biomar Microbial Technologies, H1 2015 176 Alzheimer's Disease - Pipeline by Bionature E.A. Ltd., H1 2015 177 Alzheimer's Disease - Pipeline by Biotie Therapies Corp., H1 2015 178 Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2015 179 Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Company, H1 2015 180 Alzheimer's Disease - Pipeline by Bsim2, H1 2015 181 Alzheimer's Disease - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2015 182 Alzheimer's Disease - Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 183 Alzheimer's Disease - Pipeline by Celon Pharma Sp. z o.o., H1 2015 184 Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co., Ltd., H1 2015 185 Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H1 2015 186 Alzheimer's Disease - Pipeline by Clera Inc., H1 2015 187 Alzheimer's Disease - Pipeline by Cognition Therapeutics, Inc., H1 2015 188 Alzheimer's Disease - Pipeline by Cognosci, Inc., H1 2015 189 Alzheimer's Disease - Pipeline by CoLucid Pharmaceuticals, Inc., H1 2015 190 Alzheimer's Disease - Pipeline by CoMentis, Inc., H1 2015 191 Alzheimer's Disease - Pipeline by Cortica Neurosciences, Inc., H1 2015 192 Alzheimer's Disease - Pipeline by Critical Outcome Technologies Inc., H1 2015 193 Alzheimer's Disease - Pipeline by CrystalGenomics, Inc., H1 2015 194 Alzheimer's Disease - Pipeline by D-Pharm Ltd., H1 2015 195 Alzheimer's Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 196 Alzheimer's Disease - Pipeline by Delenex Therapeutics AG, H1 2015 197 Alzheimer's Disease - Pipeline by DermaXon, LLC, H1 2015 198 Alzheimer's Disease - Pipeline by Domain Therapeutics SA, H1 2015 199 Alzheimer's Disease - Pipeline by Echo Pharmaceuticals B.V., H1 2015 200 Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H1 2015 201 Alzheimer's Disease - Pipeline by Eli Lilly and Company, H1 2015 202
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
